Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Masimo prevails in patent infringement case

This article was originally published in The Gray Sheet

Executive Summary

California federal appeals court denies Tyco/Nellcor's appeals and places a permanent injunction on the affected Nellcor pulse oximetry products, according to Masimo. In March 2004, a Los Angeles federal court jury found that Nellcor had infringed Masimo's patents and subsequently awarded Masimo $134.5 mil. According to Masimo, that figure was increased to $164 mil. when Nellcor continued to infringe on its products through May 2004. Masimo claims that damages have accrued further since the final judgment. Nellcor is the pulse oximetry market leader, with Masimo holding a distant second place spot (1"The Gray Sheet" April 5, 2004, p. 26)...

You may also be interested in...

Nellcor Seeks Reversal Of $134 Mil. Pulse Oximeter Infringement Jury Award

Tyco unit Nellcor could face treble damages and an injunction against sales following a recent jury finding of willful infringement of four Masimo pulse oximetry patents, according to Masimo

Keep Makena Under Accelerated Approval Pending More Studies, AMAG Tells US FDA

AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.

World-First Nod For Yuhan's Lung Cancer Drug, In Korea

The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts